Aptevo Therapeutics
APVO
Aptevo Therapeutics (APVO) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$151.20
- EPS estimate
- −$1,497.60
- EPS surprise
- +89.90%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 11, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 11, 2025 | −$1,497.60 | −$151.20 | +89.90% | $0.00 | SEC |
| Q1 2025 | May 15, 2025 | −$1,515.60 | −$1,580.40 | −4.28% | $0.00 | SEC |
| Q4 2024 | Feb 14, 2025 | −$2,790.00 | −$3,218.40 | −15.35% | $0.00 | SEC |
| Q3 2024 | Nov 7, 2024 | −$7,592.40 | −$6,393.60 | +15.79% | $0.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$25,707.60 | −$22,244.40 | +13.47% | $0.00 | SEC |
| Q1 2024 | May 8, 2024 | −$143,456.40 | −$132,534.00 | +7.61% | $0.00 | SEC |
| Q4 2023 | Mar 5, 2024 | −$263,736.00 | −$178,887.60 | +32.17% | $0.00 | SEC |
| Q3 2023 | Nov 14, 2023 | −$375,091.20 | −$293,040.00 | +21.88% | $0.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$656,409.60 | −$720,878.40 | −9.82% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$694,504.80 | $152,380.80 | +121.94% | $0.00 | SEC |
| Q4 2022 | Mar 30, 2023 | −$896,702.40 | −$621,244.80 | +30.72% | $0.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$955,310.40 | −$898,116.61 | +5.99% | $0.00 | SEC |
| Q2 2022 | Aug 11, 2022 | −$779,486.40 | $3,252,942.10 | +517.32% | $0.00 | SEC |
| Q1 2022 | May 12, 2022 | −$673,992.00 | −$931,867.20 | −38.26% | $3.1M | SEC |
| Q4 2021 | Mar 24, 2022 | −$758,973.60 | −$761,904.00 | −0.39% | $3.7M | SEC |
| Q3 2021 | Nov 12, 2021 | −$838,094.40 | −$849,816.00 | −1.40% | $3.1M | SEC |
| Q2 2021 | Aug 12, 2021 | −$1,172,160.00 | −$1,043,222.40 | +11.00% | $3.1M | SEC |
| Q1 2021 | May 11, 2021 | −$980,707.20 | −$1,019,779.20 | −3.98% | $2.4M | SEC |
| Q4 2020 | Mar 31, 2021 | −$908,424.00 | −$1,060,804.80 | −16.77% | $2.4M | SEC |
| Q3 2020 | Nov 10, 2020 | −$1,201,464.00 | −$1,260,072.00 | −4.88% | $1.5M | SEC |
Quarterly revenue
Frequently asked questions
When did Aptevo Therapeutics (APVO) last report earnings?
Aptevo Therapeutics last reported on Aug 11, 2025, covering fiscal Q2 2025.
Did APVO beat earnings estimates?
Yes. Aptevo Therapeutics reported EPS of −$151.20 for Q2 2025 against a −$1,497.60 estimate — a 89.90% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.